Uploaded March 2026 | Updated September 2026, 11 hours ago
Psychedelic therapy is rapidly gaining traction as a promising approach for addressing substance use disorders—from alcohol and opioids to nicotine and beyond. This session will explore how psychedelic compounds like ibogaine, ketamine, and psilocybin may help interrupt compulsive cycles, uncover root causes of addiction, and support sustained recovery.
Featuring Dr. Nathan Sackett of the UW Center for Novel Therapeutics in Addiction Psychiatry, this conversation will examine how pairing psychedelic compounds with evidence-based behavioral interventions could transform the treatment of addiction. Drawing on his team’s cautious, research-driven approach, Dr. Sackett will discuss what’s known, what remains to be discovered, and how rigorous clinical study can help bring safe, effective psychedelic-assisted therapies to those who need them most.
Nathan Sackett, MD, MS, is an addiction psychiatrist and Founding Director of the UW Center for Novel Therapeutics in Addiction Psychiatry. He completed medical and nursing school at UCSF, graduate studies at UC Berkeley, and residency and fellowship training in psychiatry and addiction psychiatry at the University of Washington, where he is now a faculty member in the Department of Psychiatry and Behavioral Sciences. His research explores how psychedelics can enhance psychotherapy and support lasting behavioral change.
April Pride is a Seattle-based creative entrepreneur and harm reduction advocate with over two decades of experience building brands at the intersection of lifestyle, cannabis, psychedelics, and women’s health. Her work has been featured in The New York Times, Forbes, Vice, and The Guardian. April is the founder of SetSet, the world’s first clinician-approved woman-focused platform for safe, accessible psychedelic integration. To learn more, follow April on Substack – aprilpride.substack.com
Presented by Town Hall Seattle and SetSet.
Psychedelic therapy is rapidly gaining traction as a promising approach for addressing substance use disorders—from alcohol and opioids to nicotine and beyond. This session will explore how psychedelic compounds like ibogaine, ketamine, and psilocybin may help interrupt compulsive cycles, uncover root causes of addiction, and support sustained recovery.
Featuring Dr. Nathan Sackett of the UW Center for Novel Therapeutics in Addiction Psychiatry, this conversation will examine how pairing psychedelic compounds with evidence-based behavioral interventions could transform the treatment of addiction. Drawing on his team’s cautious, research-driven approach, Dr. Sackett will discuss what’s known, what remains to be discovered, and how rigorous clinical study can help bring safe, effective psychedelic-assisted therapies to those who need them most.
Nathan Sackett, MD, MS, is an addiction psychiatrist and Founding Director of the UW Center for Novel Therapeutics in Addiction Psychiatry. He completed medical and nursing school at UCSF, graduate studies at UC Berkeley, and residency and fellowship training in psychiatry and addiction psychiatry at the University of Washington, where he is now a faculty member in the Department of Psychiatry and Behavioral Sciences. His research explores how psychedelics can enhance psychotherapy and support lasting behavioral change.
April Pride is a Seattle-based creative entrepreneur and harm reduction advocate with over two decades of experience building brands at the intersection of lifestyle, cannabis, psychedelics, and women’s health. Her work has been featured in The New York Times, Forbes, Vice, and The Guardian. April is the founder of SetSet, the world’s first clinician-approved woman-focused platform for safe, accessible psychedelic integration. To learn more, follow April on Substack – aprilpride.substack.com
Presented by Town Hall Seattle and SetSet.
